The new FSRH Clinical Effectiveness Unit (CEU) Guidance: Supporting Contraceptive Choices for Individuals Who Have or Have Had Breast Cancer (November 2023) has been published.
In this new guidance, we have focused on considerations for providing informed and supportive contraceptive care to individuals who have or have had breast cancer, including key information and good practice points. The guidance includes information on who needs contraception after a diagnosis of breast cancer, what the contraceptive options are after a diagnosis of breast cancer (and summarises the research evidence available to inform this), key considerations when discussing contraception and making contraceptive prescribing decisions and how best to support contraceptive decision-making.
Key messages in the guidance are that in order to achieve effective, appropriate, acceptable contraception and avoid unintended pregnancy, contraceptive discussions with people who have or have had a breast cancer need to be individualised and pragmatic, reflect the recommendations that can be made as well as what we do not know due to uncertainties from lack of evidence, and support the individual’s needs and preferences. This guidance document highlights the significant lack of direct evidence to inform health outcomes associated with use of contraception by individuals who have or have had breast cancer. This guidance was developed in consultation with a broad range of breast care, contraception and SRH experts and other key stakeholders.
Access the full guidance